title: CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality.
abstract: BACKGROUND
  The impact of early detection of CMV infections in allogeneic bone marrow transplantation (BMT) and of early treatment with ganciclovir is still uncertain.
  
  
  METHODS
  98 patients undergoing allogeneic BMT for hematologic malignancies (n = 91) or aplastic anemia (n = 7) were monitored weekly for the expression of the lower matrix protein pp65 of cytomegalovirus (CMV) on peripheral blood cells (PB) and urine sediments (U) as detected by C10 and C11 monoclonal antibodies (Clonab, Biotest) and immunoperoxidase. Bronchoalveolar lavage (BAL) cytospin preparations were also studied in patients with clinically documented interstitial pneumonia. Patients were considered to be infected with CMV if pp65 was detected in PB (n = 15) or BAL cells (n = 6), or in the presence of serum CMV-IgM with (n = 7) or without (n = 3) pp65-positive cells in urine sediments.
  
  
  RESULTS
  The overall actuarial risk at 300 days of developing a CMV infection was 35%. CMV serum/status (IgG) pre-BMT of donor and/or recipient predicted the occurrence of CMV infections post-BMT: in neg/neg donor/recipient pairs (n = 17) the actuarial risk at 300 days was 0%, compared to 41% in pairs in which donor and/or recipient were CMV seropositive (n = 81) (p = 0.001). 24/31 patients were treated with ganciclovir (DHPG), and 17 survive. Mortality of patients treated early with DHPG on the basis of CMV antigenemia was 18% compared to 42% for untreated patients (p = 0.9). Pretransplant donor/recipient seropositivity accurately predicted transplant related mortality (TBM): 6% in neg/neg pairs vs 41% in all other combinations (p = 0.008).
  
  
  CONCLUSIONS
  The risk of developing CMV infections post-BMT can be predicted by pre-transplant serostatus, diagnosed by monitoring the expression of pp65-protein and correlates with transplant related mortality. The latter appears to be reduced by early treatment with DHPG.
authors.affiliation: II Divisione di Ematologia, Ospedale San Martino, Genova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: E
authors.initials: E
authors.lastname: Tedone
authors.forename: M A
authors.initials: MA
authors.lastname: Sanna
authors.forename: F
authors.initials: F
authors.lastname: Moro
authors.forename: M T
authors.initials: MT
authors.lastname: Van Lint
authors.forename: G
authors.initials: G
authors.lastname: Grazi
authors.forename: M
authors.initials: M
authors.lastname: Balestreri
authors.forename: F
authors.initials: F
authors.lastname: Frassoni
authors.forename: D
authors.initials: D
authors.lastname: Occhini
authors.forename: F
authors.initials: F
authors.lastname: Gualandi
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000601:surgery; D000914:Antibodies, Viral / Q000097:blood; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000401:mortality; D002648:Child; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000401:mortality / Q000635:transmission*; D005260:Female; D015774:Ganciclovir / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D012189:Retrospective Studies; D012306:Risk; D016019:Survival Analysis; D014763:Viral Matrix Proteins / Q000097:blood / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D014763:Viral Matrix Proteins; D015774:Ganciclovir